Does Your Outsourcing Model Really Matter? Tufts CSDD Findings Say No
A conversation between Tufts Center for the Study of Drug Development (CSDD) Executive Director Ken Getz, MBA, and Clinical Leader Executive Editor Abby Proch

If you’ve spent any time debating your outsourcing model, the latest Tufts CSDD Impact Report might make you rethink the in-house versus full-service versus functional service provider (FSP) decision. Drawing on data from 133 clinical trials across 13 sponsors, the study found that no primary sourcing strategy delivered a statistically significant edge in start-up, enrollment, close-out timelines, or protocol amendments.
Sponsors spent more than $70 billion on contract clinical research services in 2025 — a 13% annual growth rate over the past 20 years. The decision whether and how to outsource services has real financial impact. Given the weight of the decision, Clinical Leader has tapped Ken Getz, executive director of Tufts CSDD and the study’s principal investigator, to talk through the findings.
In the Q&A below, he explains why the results make sense given today’s highly customized approach to outsourcing; why cultural fit, agility, and trust outweigh the model on paper; and why the number of providers is a different story.
Clinical Leader: Your data showed no statistically significant differences in study start-up, enrollment, close-out timelines, or protocol amendments among trials across sourcing strategies. Did that surprise you? What did you expect to find going in?
Ken Getz: Tufts CSDD researchers and working group participants were initially surprised by the findings. However, given the extremely high levels of customization that we see today in both clinical trial planning and execution, the findings make a great deal of sense. If one sourcing strategy were significantly outperforming others, the debate around which strategy offers a compelling advantage would have been settled long ago. Instead, sponsor companies are approaching outsourcing with fit-for-purpose sourcing strategies appropriate for their portfolio, cultural fit, and operating style. A successful and effective sourcing strategy is more about choosing, structuring, and managing the right relationships in an agile, adaptive, and coordinated way.
Sponsors spend a lot of time and energy picking an outsourcing model. If the primary sourcing strategy doesn’t predict performance, why else does it matter?
In our study, we’re making aggregate, industrywide comparisons. At this aggregate level, no one general sourcing strategy was associated with a performance advantage. At the individual company level, custom-tailored sourcing strategies are delivering comparable performance. The study findings suggest that the time and energy individual companies put toward selecting, structuring, and managing a collaborative partner do matter. These strategies are highly organization-specific and increasingly customized to the needs of the specific clinical trial requirements. The study findings indicate that the factors that most matter include cultural fit, flexibility, agility, trust, responsiveness, and coordination.
The mean number of quality events was nearly 10 times higher, and protocol amendments more than doubled in trials with more providers. What’s happening operationally that might drive those results? Is it fair to say that more providers are linked to poorer performance?
You’re interpreting this correctly. A larger number of service providers or intermediaries adds more complexity and fragmentation and is associated with communication and coordination inefficiencies, as well as more distributed (and often poorly established) accountability and expectations. Our research has consistently shown that the complexity and fragmentation due to larger relative numbers of intermediaries adversely impact performance, efficiency, and quality.
About The Study:
To produce the November/December 2026 Impact Report, the Tufts Center for the Study of Drug Development (CSDD) convened a working group of large and mid-sized pharmaceutical companies and collected data on 133 clinical trials and 81 development programs from 13 sponsors between late 2025 through mid-2026. About 74% of the trials were Phase 3 (most of them pivotal), and the rest were Phase 2; roughly 32% were in oncology. A companion online survey, conducted in late 2025 and early 2026, gathered ratings from 207 sponsor companies on 293 engagements across 61 CROs. The study was supported by a grant from Syneos Health. Tufts CSDD recognizes and acknowledges the sponsor companies that participated in the working group, and members of the study team — Zak Smith, Mary Jo Lamberti, Victoria Zhang, Andrew Shannon-Little, Aatif Kababi, James Man — for their contributions to this research.
About The Interviewee:
Ken Getz is the executive director of the Tufts CSDD and a research professor at the Tufts University School of Medicine. He is an internationally recognized expert on pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage, and patient engagement. A well-known speaker at conferences, symposia, universities, investor meetings, and corporations, Ken has published extensively in peer-reviewed journals, books, and the trade press. He holds board appointments in the private and public sectors. He received his MBA from Northwestern University and his bachelor’s degree from Brandeis University. Ken is also the chairman of CISCRP — a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise — and the founder of CenterWatch, a leading publisher in the clinical trials industry and one of several businesses that he has sold.